Naason Science Mail
Naason Science LinkedIn
Naason Science Facebook

Naason Science CRO (Contract Research Organization) - Where the next generation of preclinical research begins!Faster, better decisions - Based on knowledge of drug discovery and outsourcing experience, building the best integrated global preclinical services with an emphasis on innovation, reliability and commitment. Naason´s various preclinical modelling platforms are customized to suite the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a tool box of state-of-the-art technologies the allow for rapid and effective testing of preclinical drug candidates.​​ ​The Naason process starts from an in-depth knowledge of the demands of global pharmaceutical development. It involves combining superior knowledge of biological systems and system dynamics with the latest preclinical disease models, highlighting the comparative and translatable aspects and using this data to highlight the way forward for a particular drug or a drug development platform. ​The data generated from our preclinical modelling platforms is designed to provide pertinent insight and better translatability in order to allow for easier decisions made faster. Faster decision making allows a reduction in the cost of research and development. Naason Science provides the tools to study neurology, oncology, cardiovascular and metabolic therapies in a way that allows faster and better decisions. Let us show you !

AD, PD, HD, ALS, Stroke, MS, PTSD, DMD, SCA, BattenPsychiatry 

Schizophrenia, Depression, AnxietyPain 

Neuropathic-Chung, CCI, Visceral-Endometriosis, Bladder, Chemotherapy-induced pain, Central PainOncology

Syngenic Melanoma, Xenograph,  Pancreatic Cancer, Glioblastom

Eye Diseases
Dry eye disease, AMD

Metabolic diseases

NASH, DiabetesSafety & Toxicology
Mouse, rat, canine, pig, NHP, ADME PK

​>> Naason Team 

Jonathan Friedman has over 35 years’ experience in research and 20 years’ experience in drug development with startups, small enterprises and  a large, multinational corporation. He was most recently a  CNS Expert, Team and Project leader at TEVA Pharmaceuticals. Jonathan received his AB in mathematics from Oberlin College, a MSc in Physical Chemistry and PhD in Biophysics-Biochemistry from the Weizmann Institute of Science and did his postdoctoral research at Yale University, where he was also on the faculty of the medical school. His research focused on brain development and neuronal responses to stress and injury.  As the Director of Neuroscience at D-Pharm, Ltd., he led the research focusing on neurodegenerative disorders, behavior and pain as well as epilepsy and stroke. He has experience in the development of small molecule and biologic drug candidates, from the early discovery stage to regulatory submission.​

Kati Sweeney  BBA, MSc  >>>

Director of Marketing

Our personal email addresses are in form firstname[at]

Patrick J. Sweeney PhD, MBA  >>>

Founder & COO

Larry Chong Park  PhD  >>>

Founder & CEO

150+ Years of Cumulative CRO and Preclinical Drug Development Experience located in two world class cutting-edge centers of Osong Bio-medical Science Complex in Osong and DGMIF in Daegu, South Korea.

Please do not hesitate to contact us if you have any questions about our products and services. ​      

Jonathan E. Friedman  PhD


Kyung Ho Park  DVM  >>>

Team leader